Supernus Announces First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Supernus Pharma (SUPN) Tops Q1 EPS by 19c
May 9, 2022 4:42 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.43, $0.19 better than the analyst estimate of $0.24. Revenue for the quarter came in at $152 million versus the consensus estimate of $150.47 million.
GUIDANCE:
Supernus Pharma sees FY2023 revenue of $640-680 million, versus the consensus of... More
